Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study
Open accessAbstract
Objective: The high cost of novel glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) class agents often limits access and creates barriers to care. This real‐world study evaluated the efficacy of older‐generation generic antiobesity medications (AOMs) for weight maintenance after 1 year of GLP‐1 RA therapy in patients who had achieved successful weight loss. Methods: We prospectively followed patients ( N = 105) who had completed 12 months of therapy and were part of a “medical weight loss bundle,” which included 12 months of GLP‐1 RA therapy followed by 6 months of transition care. The baseline mean BMI was 36.4 kg/m 2 . Body weight outcomes were measured at 6, 12, 18, and 24 months. Results: After the medical weight loss bundle, 40 patients transitioned to generic AOMs. At 12 months, this cohort lost an average of 18.3%, 95% CI [13.0%, 23.6%] body weight from baseline, with a mean BMI of 27.9 kg/m 2 . At 18 months, they maintained the weight loss, with a mean BMI of 27.9 kg/m 2 . Subsequent follow‐up visits (average 1.5 months later) without GLP‐1 RAs showed further reduction, resulting in a total average weight loss of 25.5%, 95% CI [23.1%, 27.9%] compared to the initial visit. Conclusions: Patients successfully treated with GLP‐1 RAs can maintain their weight loss using generic older‐generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several observational studies have shown that using glucose-lowering agents in combination with or as follow-up to GLP-1RA therapy helps mitigate rebound effects and sustain metabolic improvements.
“Several observational studies have shown that using these agents either in combination with, or as follow-up to, GLP-1RA therapy helps mitigate rebound effects and sustain metabolic improvements, particularly when transitioning off GLP-1RAs.3,41”
From Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis (2025) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · see citing works
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · see citing works
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414 · see citing works
Metformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402 · see citing works
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · see citing works
Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0146-4 · Cited by 307 · see citing works
Metaflammation in obesity and its therapeutic targeting
Schleh, M. W., Caslin, H. L., Garcia, J. N., Mashayekhi, M., Srivastava, G., Bradley, A. B., & Hasty, A. H. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf9382 · Cited by 191 · see citing works
Self-citationDeFronzo, R. A., Buse, J. B., Kim, T., Burns, C. M., Skare, S., Baron, A., & Fineman, M. S. (2016) · Diabetologia · doi:10.1007/s00125-016-3992-6 · Cited by 131 · see citing works
Schenk, S., Harber, M. P., Shrivastava, C. R., Burant, C., & Horowitz, J. F. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.175489 · Cited by 123 · see citing works
Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18 · see citing works
Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review
Kułak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.96908 · Cited by 18 · see citing works
Srivastava, G., & Buffington, C. K. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0092-3 · Cited by 10 · see citing works
Self-citationShould I consider metformin therapy for weight loss in patients with obesity but without diabetes?
Rodriguez, P., Pantalone, K. M., Griebeler, M. L., & Burguera, B. G. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22096 · Cited by 9 · see citing works
Specialized Medical Weight Management Intervention for High-Risk Obesity
Srivastava, G., Parris, C., Johnson, J., Barnes, E., Cunningham, B. L., Stimson, C. J., Niswender, K. D., & Poon, S. J. (2021) · Journal of health economics and outcomes research · doi:10.36469/001c.24896 · Cited by 6 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [13]Donavon B, Johnson JQ. Topiramate and phentermine. StatPearls. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK482165/ 29489234
- [14]Huecker MR, Smiley A, Saadabadi A. Bupropion. StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK470212/ 29262173
Cited by
Sorted by citations
Tzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73 · see citing works
“3,41 Although two included RCTs investigated GLP-1RA discontinuation in type 1 diabetes, these agents are not approved for this indication.”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 34 · see citing works
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 31 · see citing works
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 15 · see citing works
Less frequent dosing of <scp>GLP</scp>‐1 receptor agonists as a viable weight maintenance strategy
Wu, C. C., Cengiz, A., & Lawley, S. D. (2025) · Obesity · doi:10.1002/oby.24302 · Cited by 9 · see citing works
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7 · see citing works
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7 · see citing works
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 11 · see citing works
Abdel‐Bary, M., Brody, A., Schmitt, J., Prieto, K., Wetzel, A. N., & Juo, Y. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100658 · Cited by 5 · see citing works
Learning from the roundtable on obesity solutions experiences: A 10-year anniversary point of view
Pronk, N. P., Dietz, W. H., Economos, C. D., Eneli, I., & Arena, R. A. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.01.003 · Cited by 4 · see citing works
Targeting metabolic syndrome with ALIAmides: A novel multi-mechanistic approach
Palenca, I., Masulli, M., Rurgo, S., Sarnelli, G., & Esposito, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118611 · Cited by 3 · see citing works
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3 · see citing works
Tipping the Scales: Strategies to Improve Anti‐Obesity Medication Access and Affordability
Komé, A. M., Boykin, A. R., Johnson-Jennings, A., & Coviello, A. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70118 · Cited by 1 · see citing works
Abusnana, S., Sabbour, H. M., Afandi, B. O., Farghaly, M., Farooqi, M. H., Hafidh, K., Hassanein, M. M., Jabbar, A., Shehab, A., Kalimat, R., et al. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s579970 · Cited by 1 · see citing works
Abdelaziz, O., Zayed, Z. G., Khalafallah, M. A., Hanafy, M. A., Hadhoud, A. M., & Elmenawi, K. A. (2026) · Arthroplasty · doi:10.1186/s42836-026-00375-w · Cited by 1 · see citing works
Arena, R. A., & Pronk, N. P. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102966 · Cited by 1 · see citing works
How to keep weight off after obesity drugs
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-01770-0 · Cited by 1 · see citing works
Srivastava, G., Madhar, A., & Chen, Y. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251380864
Self-citationТуркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies
Durma, A. C., & Czupryniak, L. (2026) · Nutrients · doi:10.3390/nu18162602
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
- Authors
- Paddu, N. U., Lawrence, B., Wong, S., Poon, S. J., & Srivastava, G.
- Affiliations
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Srivastava, Gitanjali
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2024-11-18
- Volume
- 32
- Issue
- 12
- Pages
- 2255-2263
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- PMC
- PMC11589535
- OpenAlex
- W4404509034
- Cited by
- 22
- References
- 15
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 1
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Obesity (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- weight maintenance, anti-obesity drugs, GLP-1 receptor agonists, generic drugs, obesity treatment, weight loss, cost-effectiveness, care transitions, body mass index
- MeSH terms
- Body Weight Maintenance, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Obesity, Prospective Studies, Weight Loss, Body Mass Index, Drugs, Generic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
